Within one’s body, approximately 100 trillion microorganisms, mainly bacteria, coexist. Surprisingly, these microorganisms outnumber the number of cells in the body by a staggering 300-fold. These tiny inhabitants play a crucial role, producing both beneficial and harmful metabolites that your body cannot generate. Essentially, they function as a concealed vital organ within you. Research indicates that the majority of these microorganisms, about 95%, reside in your gut, where they exert a significant influence on approximately 70% of your immune system and are closely linked to the development of 90% of non-communicable diseases. Consequently, the gut microbiome stands as one of the most remarkable scientific discoveries of the past decade.
Unlocking the secrets of one's unique gut microbiome composition holds a key to health monitoring, predicting medication effectiveness, and tailoring treatments. Notably, the gut microbiome closely correlates with dietary and lifestyle choices and can be modulated to prevent health issues rather than merely correcting them. However, the lack of comprehensive knowledge and databases in Southeast Asia represents a significant gap in this field. Bridging this gap promises to yield invaluable insights and drive future healthcare breakthroughs.
Utilising 16S rRNA sequencing technology, precise identification and quantification of an individual's gut microbial composition from stool sample has become possible. Using advanced algorithms to analyse raw gut microbiome data, honed through a curated list of microbial biomarkers and a specialised ASEAN gut microbiota database, the technology is able to provide a comprehensive and individualised health report that assesses the gut microbiome's current state correlating that to an individual's health and potential disease risks.
Moreover, this analysis enables the creation of personalised dietary recommendations, with the goal of enhancing an individual's healthspan. The continuously expanding gut microbiome database serves a dual purpose: facilitating the discovery of microbial biomarkers and deepening the understanding of disease pathways, uniquely tailored to ASEAN populations. This cutting-edge approach leverages advanced sequencing technology, data analysis, and regional insights to provide valuable insights into gut health and promote overall well-being.
This technology spans a wide spectrum of healthcare and well-being applications:
The global human microbiome market size for 2023 is projected to reach USD 770 million, exhibiting a remarkable compound annual growth rate (CAGR) of 16.37%.
This growth is underpinned by four major trends shaping the microbiome therapeutics market:
This technology has enabled advanced personalised health prevention solutions that have been meticulously crafted for ASEAN individuals, featuring: